Kerry Shannon Burke

Transactional

Representative Capital Markets Transactions

• Uber in connection with its initial public offering and with offerings of high yield notes and convertible notes.
• Humacyte in connection with its going public deSPAC transaction and related PIPE offering and in subsequent equity financings.
• Cameco in connection with its $747.6 million equity financing in connection with its acquisition of an interest in Westinghouse.
• Eli Lilly in various debt offerings, including $10.9 billion of senior notes, €3.7 billion of Eurobonds, ¥79.9 billion of senior notes and CHF1.2 billion of notes.
• Avnet in $1.2 billion of registered debt offerings.
• Republic Services in $6.3 billion of senior notes offerings.
• Omeros Corporation in various common stock and pre-funded warrant offerings, a $210 million convertible notes offering and at-the-market facilities.
• LanzaTech in connection with its going public deSPAC transaction and related PIPE financing.
• NewAmsterdamPharma in connection with its going public deSPAC transaction and related PIPE financing.
• Edison International in a $1.5 billion at-the-market facility.
• REGENXBIO in various common stock and pre-funded warrant offerings.
• Salix Pharmaceuticals in a $750.0 million high yield bond offering.
• Pepco Holdings and its subsidiaries in over $9.6 billion of private and public securities offerings, including issuances of first mortgage bonds, senior notes, “fading lien” bonds, tax-exempt bonds and common stock.
• A foreign gaming company in a U.S. offering of ordinary shares.
  Various public company issuers, including Bristol-Myers Squibb, Eli Lilly and Pepco Holdings in debt tender offers and related consent solicitations.
• XLHealth in a $240 million private placement to a private equity investor and in a preferred stock investment by venture capital investors.

Representative Finance Transactions

• Avnet in its $1.25 billion senior unsecured credit facility and $900 million securitization facility and in multiple refinancings thereunder.
• Uber in multiple refinancings of its $2.3 billion revolving credit facility and its $2.5 billion term loan facility.
• A pharmaceutical company in its $10 billion unsecured credit facility.
• A pharmaceutical company in $21.8 billion of various unsecured credit facilities.
• A foreign gaming company in its syndicated secured term loan B facility and its secured “sidecar” facility and in multiple refinancings thereunder.
• Pepco Holdings and its subsidiaries in their significant finance matters, including syndicated and bilateral credit facilities, commercial paper programs, bridge acquisition facilities, a credit intermediation arrangement and various swap transactions.
• SandRidge Energy in its $900 million secured (borrowing base) credit facility.
• A private specialty pharmaceutical company in its senior secured credit facility.
• Various borrowers in connection with acquisition finance facilities.
• Lenders in the refinancing of the senior secured credit facility for the Capital One Arena.
• Various emerging growth companies in bridge financings and in secured lines of credit.

Advisory

• Various public companies and their boards on securities reporting and corporate governance matters, including board and committee independence, committee charters, codes of ethics, governance guidelines, insider trading, share repurchase programs, internal and disclosure controls, succession planning and management transitions, fiduciary duties, cybersecurity, related party transactions, ESG disclosures, shareholder proposals and engagement and similar matters.
• Various public and private companies in derivatives transactions.
• Various private funds with the investment adviser registration process, including drafting Form ADVs and compliance policies and procedures.
• Various investment advisers with ongoing compliance advice, including on conflicts of interest, fees, custody, pay-to-play, performance advertising, foreign adviser issues and SEC examination issues..